Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients

被引：0
作者：
Schmittel, A
Siehl, JM
Schulze, M
Schulze, K
Thiel, E
Keilholz, U
机构：
[1] Univ Med Berlin, Dept Med Hematol Oncol & Transfusionmed 3, Charite, D-12200 Berlin, Germany
[2] Univ Med Berlin, Dept Med Cardiol & Pulmol 2, Charite, D-12200 Berlin, Germany
[3] Kreiskrankenhaus Zittau, Dept Hematol & Oncol, D-02763 Zittau, Germany
来源：
ANTICANCER RESEARCH | 2005年 / 25卷 / 2B期
关键词：
NSCLC; triple chemotherapy; carboplatin; paclitaxel; vinorelbine;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Vinorelbine was added to carboplatin plus paclitaxel to determine efficacy and toxicity in non-small cell lung cancer (NSCLC) patients with good performance status. Patients and Methods: Vinorelbine 30 mg/m(2) plus paclitaxel 175 mg/m(2) plus carboplatin AUC 5 was administered every three weeks for a maximum of 6 cycles. Results: One out of 37 patients had a complete and 12 a partial remission (35% response rate). Six patients (16%) had disease stabilization and 18 (49%) progressed. Grade III or IV neutropenia occurred in 11 (30%) and febrile neutropenia in 6 (16%) patients. Grade III/IV neuropathy was observed in 6 (16%) patients. The median time to progression was 6 months (95% CI 4.0 - 8.0), and median survival 11 months (95% CI 8.3 - 13.7). One- and two-year survival was 41% (95% CI 24 - 58) and 24% (95% CI 8.7 - 39.1), respectively. Conclusion: This triplechemotherapy combination is feasible. The response rates justify further investigation in similar patient subgroups.
引用
收藏
页码：1333 / 1336
页数：4
相关论文
共 14 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer [J].
Billingham, LJ ;
Cullen, MH .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1671-1675
[3]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[4]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[5]  
Comella P, 2000, Oncology (Williston Park), V14, P35
[6]   Cisplatin/carboplatin plus etoposide plus vinorelbine in advanced non-small-cell lung cancer: A multicentre randomised trial [J].
Comella, P ;
Frasci, G ;
DeCataldis, G ;
Panza, N ;
Cioffi, R ;
Curcio, C ;
Belli, M ;
Bianco, A ;
Ianniello, G ;
Maiorino, L ;
DellaVittoria, M ;
Perchard, J ;
Comella, G .
BRITISH JOURNAL OF CANCER, 1996, 74 (11) :1805-1811
[7]   Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer:: A randomized phase III study of the Italian lung cancer project [J].
Crinò, L ;
Scagliotti, GV ;
Ricci, S ;
De Marinis, F ;
Rinaldi, M ;
Gridelli, C ;
Ceribelli, A ;
Bianco, R ;
Marangolo, M ;
Di Costanzo, F ;
Sassi, M ;
Barni, S ;
Ravaioli, A ;
Adamo, V ;
Portalone, L ;
Cruciani, G ;
Masotti, A ;
Ferrara, G ;
Gozzelino, F ;
Tonato, M .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3522-3530
[8]   Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma - A Minnie Pearl cancer research network trial [J].
Greco, FA ;
Gray, JR ;
Thompson, DS ;
Burris, HA ;
Erland, JB ;
Barton, JH ;
Litchy, S ;
Houston, GA ;
Butts, JA ;
Webb, C ;
Scott, C ;
Hainsworth, JD .
CANCER, 2002, 95 (06) :1279-1285
[9]   CREATININE CLEARANCE - BEDSIDE ESTIMATE [J].
JELLIFFE, RW .
ANNALS OF INTERNAL MEDICINE, 1973, 79 (04) :604-605
[10]   Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy [J].
Jeremic, B ;
Milicic, B ;
Dagovic, A ;
Aleksandrovic, J ;
Nikolic, N .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (02) :114-122
12